In 2009, Johnson & Johnson Innovation – JJDC invested in Navitor Pharmaceuticals, a company exploring mTORC1, which plays a key role in dysregulation of cell proliferation, inflammation, and metabolic activities. A few years later, Navitor applied and was granted residency at JLABS @ LabCentral and continued its focus in the mTORC1 space.

After years of further research, Navitor created a subsidiary company, Anakuria, to focus on mTORC1 inhibitors to explore solutions for autosomal dominant polycystic kidney disease (ADPKD), a commonly inherited disorder that causes the kidneys to enlarge and lose function over time.

Navitor’s collaboration with Johnson & Johnson Innovation came full circle with the acquisition of Anakuria by Janssen Pharmaceuticals, providing Janssen with a potential first-in-class opportunity in ADPKD.

With decades of experience in developing, manufacturing and commercializing innovative therapies for patients su􀉡ering from a broad range of diseases and conditions, Janssen is ideally positioned to rapidly advance our program in the clinic.

Tom Hughes
President and Chief Executive Officer of Navitor Pharmaceuticals LLC